No Need for Acquisitions over Next 5 Years, 12 NMEs to Counter Patent Cliff: Takeda CEO

Takeda CEO Christophe Weber Takeda Pharmaceutical CEO Christophe Weber is confident that the company needs no acquisition deal over the next five years before its major products starts going off-patent as 12 new molecular entities (NMEs) in its pipeline are...read more